A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Clinical trial NCT03303625 · COMPLETED

Trial details

NCT number: NCT03303625
Sponsor: Janssen Vaccines & Prevention B.V.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Respiratory Syncytial Viruses Respiratory Tract Infections

Start date: 2017-11-29
Primary completion: 2020-04-21
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.